Zyclara receives positive opinion from the Committee for Human Medicinal Products in the European Union
The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding marketing authorization of Zyclara (treatment of actinic keratoses on large skin areas). The European Commission generally follows the recommendations of the CHMP (EMA) and announces its final decision within three months after the recommendation. Following an approval, the marketing authorization is valid across the European Union.
"I’m pleased that the CHMP has adopted a positive opinion for Zyclara, which will further strengthen Meda’s product portfolio in dermatology. Our launch pipeline looks very promising", said Anders Lönner, CEO of Meda AB.
About actinic keratosis and Zyclara
Actinic keratosis (AK), early skin carcinoma in situ is an under-diagnosed and under-treated disease and the number of affected patients is increasing. There is a close regional coexistence of invisible (subclinical AK lesions) as well as clinical visible AK lesions on areas of sun exposed skin - a phenomenon which is called field cancerization.
Zyclara - an imiquimod 3.75% cream - is to date the first clinically proven treatment option which can detect and eliminate subclinical as well as clinical AK lesions on large areas of the skin. Zyclara has shown in a large clinical development program to be an effective therapy in eliminating both kinds of AK lesions and with low recurrence rate.
“Zyclara represents a breakthrough product in actinic keratosis management and could transform how this disease is managed”, said Prof. Eggert Stockftleth, Professor of dermatology, Charité, Berlin and founder of the EpiDerm project which is sponsored by the European Union and has the aim to raise awareness of AK.
For further inquiries, please contact:
Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878 anders.larnholt@meda.se
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
Forward-looking statements
This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda’s potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “forecast”, “believe” or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda’s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB’s interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.
